Ocular pharmacokinetics of fluocinolone acetonide after Retisert™ intravitreal implantation in rabbits over a 1-year period

Journal of Ocular Pharmacology and Therapeutics

Volumn 20, Issue 3, 2004, Pages 269-275

  Driot, Jean Yves ^a   Novack, Gary D ^b   Rittenhouse, Kay D ^a,c   Milazzo, Chris ^d   Pearson, P Andrew ^e  

^a BAUSCH AND LOMB   (United States)

^b PHARMALOGIC DEVELOPMENT INC   (United States)

^c PFIZER INC   (United States)

^d Control Delivery Systems ^*  (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CILIARY BODY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG URINE LEVEL; EYE INFLAMMATION; IMPLANT; IRIS; LENS; NONHUMAN; POSTERIOR EYE CHAMBER; RABBIT; RETINA; VITREOUS BODY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE; FLUOCINOLONE ACETONIDE; RABBITS; TIME FACTORS; VITREOUS BODY;

EID: 3042763334     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/1080768041223611     Document Type: Article

References (12)

1. Stem, A.L., Taylor, D.M., Dalburg, L.A., and Cosentino, R.T. Pseudophakic cystoid maculopathy: A study of 50 cases. Ophthalmology 88:942-946, 1981.
2. Leopold, I.H., and Gaster, R. Ocular inflammation and anti-inflammatory drugs. In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, eds. The Cornea. New York: Churchill Livingstone, 1987, p. 70.
3. Ashton, P., Blandford, D.L., Pearson, P.A., Jaffe, G.J., Martin, D.F., and Nussenblatt, R.B. Review: Implants. J. Ocul. Pharmacol. 10:691-701, 1994.
4. Musch, D.C., Martin, D.F., Gordon, J.F., Davis, M.D., and Kuppermann, B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant: The Ganciclovir Implant Study Group. N. Engl. J. Med. 337:83-90, 1997.
5. Martin, D.F., Parks, D.J., Mellow, S.D., et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch. Ophthalmol. 112:1531-1539, 1994.
6. Cunningham, E.T., Jr., and Nozik, R.A. Uveitis: Diagnostic approach and ancillary analysis. In: Tasman W, Jaeger EA, eds. Schwab, I.R., and Tessler, H.H., Volume eds. Duane's Clinical Ophthalmology. Philadelphia: J.B. Lippincott, 1998, pp. 1-25.
7. Jampol, L.M. Pharmacologic therapy of aphakic cystoid macular edema: A review. Ophthalmology 89:891-897, 1982.
8. Martidis, A., Duker, J.S., Greenberg, P.B., Rogers, A.H., Puliafito, C.A., Reichel, E., and Baumal, C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927, 2002.
9. Hainsworth, D.P., Pearson, P.A., Conklin, J.D., and Ashton, P. Sustained release intravitreal dexamethasone. J. Ocul. Pharmacol. Ther. 12:57-63, 1996.
10. Jaffe, G.J., Yang, C.H., Guo, H., Denny, J.P., Lima, C., and Ashton, P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest. Ophthalmol. Vis. Sci. 41:3569-3575, 2000.
11. Jaffe, G.J., Ben Nun, J., Guo, H., Dunn, J.P., and Ashton, P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107:2024-2033, 2000.
12. Blois, M.S., and Taskovich, L. The reversible binding of some aromatic and cyclic compounds to biopolymers in vitro. J. Invest. Dermatol. 53:344-350, 1969.